FMP

FMP

Enter

DBTX - Decibel Therapeutics...

photo-url-https://images.financialmodelingprep.com/symbol/DBTX.png

Decibel Therapeutics, Inc.

DBTX

NASDAQ

Inactive Equity

Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. It is also developing DB-ATO and AAV.201, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the vestibule; DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial; AAV.103 to restore hearing in individuals with a gap junction beta-2 (GJB2) deficiency; AAV.104 to restore hearing in individuals with stereocilin (STRC) deficiency; and cochlear hair cell regeneration program, an AAV-based gene therapy that utilizes cell-selective expression of reprogramming factors to convert supporting cells into outer hair cells. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts.

4.91 USD

-0.04 (-0.815%)

About

ceo

Dr. Laurence E. Reid Ph.D.

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. It is also developing DB-ATO and AAV.201, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the vestibule; DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial; AAV.103 to restore hearing in individuals with a gap junction beta-2 (GJB2) deficiency; AAV.104 to restore hearing in individuals with stereocilin (STRC) deficiency; and cochlear hair cell regeneration program, an AAV-based gene therapy that utilizes cell-selective expression of reprogramming factors to convert supporting cells into outer hair cells. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts.

CIK

0001656536

ISIN

US24343R1068

CUSIP

24343R106

Address

1325 Boylston Street

Phone

617 370 8701

Country

US

Employee

68

IPO Date

Feb 12, 2021

Key Executives

Name

Title

Pay

Year Born

Ms. Elaine Cope M.B.A.

Vice President of Operations

0

N/A

Dr. Laurence E. Reid Ph.D.

Pres & Chief Executive Officer

742.98k

1964

Mr. M. Charles Liberman

Co-Founder & Member of Scientific Adviso...

0

N/A

Dr. Albert S. B. Edge

Co-Founder & Member of Scientific Adviso...

0

1955

Ms. Elaine Cope

Vice President of Operations

0

N/A

Dr. Gabriel Corfas

Co-Founder & Member of Scientific Adviso...

0

N/A

Dr. Ulrich Müller

Co-Founder & Member of Scientific Adviso...

0

N/A

Mr. James B. Murphy

Interim Chief Financial Officer, Princip...

0

1957

Ms. Anna Trask M.A.

Executive Vice President & Chief People ...

481.23k

1958

Mr. John J. Lee

Executive Vice President & Chief Devel. ...

596.15k

1968

Mr. Geoff Horwitz

Vice President of Corporation Devel. & H...

0

N/A

Mr. Joe Burns Ph.D.

Senior Vice President of Discovery

0

N/A

As of December 31, 2024, the total employee count stands at 68, with compensation values reflecting the last fiscal year ending on that date. Pay encompasses salary, bonuses, etc., All figures are in USD.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep